BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chiang HL, Lin CH. Altered Gut Microbiome and Intestinal Pathology in Parkinson's Disease. J Mov Disord 2019;12:67-83. [PMID: 31158941 DOI: 10.14802/jmd.18067] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Costa HN, Esteves AR, Empadinhas N, Cardoso SM. Parkinson's Disease: A Multisystem Disorder. Neurosci Bull 2022. [PMID: 35994167 DOI: 10.1007/s12264-022-00934-6] [Reference Citation Analysis]
2 Yadav S, Dwivedi A, Tripathi A, Tripathi AK. Therapeutic potential of Short Chain Fatty acid production by gut microbiota in Neurodegenerative disorders. Nutrition Research 2022. [DOI: 10.1016/j.nutres.2022.07.007] [Reference Citation Analysis]
3 Soni R, Shah J. Deciphering Intertwined Molecular Pathways Underlying Metabolic Syndrome Leading to Parkinson's Disease. ACS Chem Neurosci 2022. [PMID: 35856649 DOI: 10.1021/acschemneuro.2c00165] [Reference Citation Analysis]
4 Jo S, Kang W, Hwang YS, Lee SH, Park KW, Kim MS, Lee H, Yoon HJ, Park YK, Chalita M, Lee JH, Sung H, Lee JY, Bae JW, Chung SJ. Oral and gut dysbiosis leads to functional alterations in Parkinson's disease. NPJ Parkinsons Dis 2022;8:87. [PMID: 35798742 DOI: 10.1038/s41531-022-00351-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Berger AA, Winnick A, Izygon J, Jacob BM, Kaye JS, Kaye RJ, Neuchat EE, Kaye AM, Alpaugh ES, Cornett EM, Han AH, Kaye AD. Opicapone, a Novel Catechol-O-methyl Transferase Inhibitor, for Treatment of Parkinson's Disease "Off" Episodes. Health Psychol Res 2022;10:36074. [PMID: 35774903 DOI: 10.52965/001c.36074] [Reference Citation Analysis]
6 Beserra-Filho JIA, Maria-Macêdo A, Silva-Martins S, Custódio-Silva AC, Soares-Silva B, Silva SP, Lambertucci RH, de Souza Araújo AA, Lucchese AM, Quintans-Júnior LJ, Santos JR, Silva RH, Ribeiro AM. Lippia grata essential oil complexed with β-cyclodextrin ameliorates biochemical and behavioral deficits in an animal model of progressive parkinsonism. Metab Brain Dis 2022. [PMID: 35779151 DOI: 10.1007/s11011-022-01032-2] [Reference Citation Analysis]
7 Tsafaras G, Baekelandt V. The role of LRRK2 in the periphery: link with Parkinson's disease and inflammatory diseases. Neurobiol Dis 2022;172:105806. [PMID: 35781002 DOI: 10.1016/j.nbd.2022.105806] [Reference Citation Analysis]
8 Romo-Vaquero M, Fernández-Villalba E, Gil-Martinez AL, Cuenca-Bermejo L, Espín JC, Herrero MT, Selma MV. Urolithins: potential biomarkers of gut dysbiosis and disease stage in Parkinson's patients. Food Funct 2022;13:6306-16. [PMID: 35611932 DOI: 10.1039/d2fo00552b] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Nishiwaki H, Ito M, Hamaguchi T, Maeda T, Kashihara K, Tsuboi Y, Ueyama J, Yoshida T, Hanada H, Takeuchi I, Katsuno M, Hirayama M, Ohno K. Short chain fatty acids-producing and mucin-degrading intestinal bacteria predict the progression of early Parkinson's disease. NPJ Parkinsons Dis 2022;8:65. [PMID: 35650236 DOI: 10.1038/s41531-022-00328-5] [Reference Citation Analysis]
10 Just MK, Gram H, Theologidis V, Jensen PH, Nilsson KPR, Lindgren M, Knudsen K, Borghammer P, Van Den Berge N. Alpha-Synuclein Strain Variability in Body-First and Brain-First Synucleinopathies. Front Aging Neurosci 2022;14:907293. [DOI: 10.3389/fnagi.2022.907293] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
11 Li YY, Zhou TT, Zhang Y, Chen NH, Yuan YH. Distribution of α-Synuclein Aggregation in the Peripheral Tissues. Neurochem Res 2022. [PMID: 35348944 DOI: 10.1007/s11064-022-03586-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Ding Z, Zhao Y, Liu J, Ge W, Xu X, Wang S, Zhang J. Dietary Succinoglycan Riclin Improves Glycemia Control in Mice with Type 2 Diabetes. J Agric Food Chem 2022. [PMID: 35132858 DOI: 10.1021/acs.jafc.1c06881] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Van Den Berge N, Ulusoy A. Animal models of brain-first and body-first Parkinson's disease. Neurobiology of Disease 2022;163:105599. [DOI: 10.1016/j.nbd.2021.105599] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
14 Folke J, Ferreira N, Brudek T, Borghammer P, Van Den Berge NVD. Passive Immunization in Alpha-Synuclein Preclinical Animal Models. Biomolecules 2022;12:168. [DOI: 10.3390/biom12020168] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
15 Bicknell B, Liebert A, McLachlan CS, Kiat H. Microbiome Changes in Humans with Parkinson's Disease after Photobiomodulation Therapy: A Retrospective Study. J Pers Med 2022;12:49. [PMID: 35055364 DOI: 10.3390/jpm12010049] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Ghyselinck J, Verstrepen L, Moens F, Van Den Abbeele P, Bruggeman A, Said J, Smith B, Barker LA, Jordan C, Leta V, Chaudhuri KR, Basit AW, Gaisford S. Influence of probiotic bacteria on gut microbiota composition and gut wall function in an in-vitro model in patients with Parkinson's disease. Int J Pharm X 2021;3:100087. [PMID: 34977556 DOI: 10.1016/j.ijpx.2021.100087] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
17 Anis E, Xie A, Brundin L, Brundin P. Digesting recent findings: gut alpha-synuclein, microbiome changes in Parkinson's disease. Trends Endocrinol Metab 2021:S1043-2760(21)00268-X. [PMID: 34949514 DOI: 10.1016/j.tem.2021.11.005] [Reference Citation Analysis]
18 Lin CH, Lin HY, Ho EP, Ke YC, Cheng MF, Shiue CY, Wu CH, Liao PH, Hsu AY, Chu LA, Liu YD, Lin YH, Tai YC, Shun CT, Chiu HM, Wu MS. Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice Through Activating TNF-α Pathway. Mov Disord 2021. [PMID: 34918781 DOI: 10.1002/mds.28890] [Reference Citation Analysis]
19 Kim TJ, Lee H. Benefits of Helicobacter pylori Eradication on Extragastric Diseases. Korean J Helicobacter Up Gastrointest Res 2021;21:275-86. [DOI: 10.7704/kjhugr.2021.0041] [Reference Citation Analysis]
20 Shan J, Qu Y, Wang S, Wei Y, Chang L, Ma L, Hashimoto K. Regulation of neurotoxicity in the striatum and colon of MPTP-induced Parkinson's disease mice by gut microbiome. Brain Res Bull 2021;177:103-10. [PMID: 34560239 DOI: 10.1016/j.brainresbull.2021.09.009] [Reference Citation Analysis]
21 Bindas AJ, Kulkarni S, Koppes RA, Koppes AN. Parkinson's disease and the gut: Models of an emerging relationship. Acta Biomater 2021;132:325-44. [PMID: 33857691 DOI: 10.1016/j.actbio.2021.03.071] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
22 Natale G, Ryskalin L, Morucci G, Lazzeri G, Frati A, Fornai F. The Baseline Structure of the Enteric Nervous System and Its Role in Parkinson's Disease. Life (Basel) 2021;11:732. [PMID: 34440476 DOI: 10.3390/life11080732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Gallop A, Weagley J, Paracha SU, Grossberg G. The Role of The Gut Microbiome in Parkinson's Disease. J Geriatr Psychiatry Neurol 2021;34:253-62. [PMID: 34219519 DOI: 10.1177/08919887211018268] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
24 Ray B, Mahalakshmi AM, Tuladhar S, Bhat A, Srinivasan A, Pellegrino C, Kannan A, Bolla SR, Chidambaram SB, Sakharkar MK. "Janus-Faced" α-Synuclein: Role in Parkinson's Disease. Front Cell Dev Biol 2021;9:673395. [PMID: 34124057 DOI: 10.3389/fcell.2021.673395] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Lerner A. The intestinal luminal sources of α-synuclein: a gastroenterologist perspective. Nutr Rev 2021:nuab024. [PMID: 33942062 DOI: 10.1093/nutrit/nuab024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Murros KE, Huynh VA, Takala TM, Saris PEJ. Desulfovibrio Bacteria Are Associated With Parkinson's Disease. Front Cell Infect Microbiol 2021;11:652617. [PMID: 34012926 DOI: 10.3389/fcimb.2021.652617] [Reference Citation Analysis]
27 Van Den Berge N, Ferreira N, Mikkelsen TW, Alstrup AKO, Tamgüney G, Karlsson P, Terkelsen AJ, Nyengaard JR, Jensen PH, Borghammer P. Ageing promotes pathological alpha-synuclein propagation and autonomic dysfunction in wild-type rats. Brain 2021;144:1853-68. [PMID: 33880502 DOI: 10.1093/brain/awab061] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
28 Chen SJ, Chi YC, Ho CH, Yang WS, Lin CH. Plasma Lipopolysaccharide-Binding Protein Reflects Risk and Progression of Parkinson's Disease. J Parkinsons Dis 2021;11:1129-39. [PMID: 33720853 DOI: 10.3233/JPD-212574] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Cho J, Park YJ, Gonzales-Portillo B, Saft M, Cozene B, Sadanandan N, Borlongan CV. Gut dysbiosis in stroke and its implications on Alzheimer's disease-like cognitive dysfunction. CNS Neurosci Ther 2021;27:505-14. [PMID: 33464726 DOI: 10.1111/cns.13613] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Karunaratne TB, Okereke C, Seamon M, Purohit S, Wakade C, Sharma A. Niacin and Butyrate: Nutraceuticals Targeting Dysbiosis and Intestinal Permeability in Parkinson's Disease. Nutrients 2020;13:E28. [PMID: 33374784 DOI: 10.3390/nu13010028] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Nishiwaki H, Hamaguchi T, Ito M, Ishida T, Maeda T, Kashihara K, Tsuboi Y, Ueyama J, Shimamura T, Mori H, Kurokawa K, Katsuno M, Hirayama M, Ohno K. Short-Chain Fatty Acid-Producing Gut Microbiota Is Decreased in Parkinson's Disease but Not in Rapid-Eye-Movement Sleep Behavior Disorder. mSystems 2020;5:e00797-20. [PMID: 33293403 DOI: 10.1128/mSystems.00797-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Marogianni C, Sokratous M, Dardiotis E, Hadjigeorgiou GM, Bogdanos D, Xiromerisiou G. Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disease. Int J Mol Sci 2020;21:E8421. [PMID: 33182554 DOI: 10.3390/ijms21228421] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
33 Hopper CP, De La Cruz LK, Lyles KV, Wareham LK, Gilbert JA, Eichenbaum Z, Magierowski M, Poole RK, Wollborn J, Wang B. Role of Carbon Monoxide in Host-Gut Microbiome Communication. Chem Rev 2020;120:13273-311. [PMID: 33089988 DOI: 10.1021/acs.chemrev.0c00586] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
34 Fouka M, Mavroeidi P, Tsaka G, Xilouri M. In Search of Effective Treatments Targeting α-Synuclein Toxicity in Synucleinopathies: Pros and Cons. Front Cell Dev Biol 2020;8:559791. [PMID: 33015057 DOI: 10.3389/fcell.2020.559791] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
35 van IJzendoorn SCD, Derkinderen P. The Intestinal Barrier in Parkinson's Disease: Current State of Knowledge. J Parkinsons Dis 2019;9:S323-9. [PMID: 31561386 DOI: 10.3233/JPD-191707] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
36 Nishiwaki H, Ito M, Ishida T, Hamaguchi T, Maeda T, Kashihara K, Tsuboi Y, Ueyama J, Shimamura T, Mori H, Kurokawa K, Katsuno M, Hirayama M, Ohno K. Meta-Analysis of Gut Dysbiosis in Parkinson's Disease. Mov Disord 2020;35:1626-35. [PMID: 32557853 DOI: 10.1002/mds.28119] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 18.5] [Reference Citation Analysis]
37 Pellegrini C, Antonioli L, Calderone V, Colucci R, Fornai M, Blandizzi C. Microbiota-gut-brain axis in health and disease: Is NLRP3 inflammasome at the crossroads of microbiota-gut-brain communications? Prog Neurobiol 2020;191:101806. [PMID: 32473843 DOI: 10.1016/j.pneurobio.2020.101806] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
38 Ilie OD, Ciobica A, McKenna J, Doroftei B, Mavroudis I. Minireview on the Relations between Gut Microflora and Parkinson's Disease: Further Biochemical (Oxidative Stress), Inflammatory, and Neurological Particularities. Oxid Med Cell Longev 2020;2020:4518023. [PMID: 32089768 DOI: 10.1155/2020/4518023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
39 Zhu S, Jiang Y, Xu K, Cui M, Ye W, Zhao G, Jin L, Chen X. The progress of gut microbiome research related to brain disorders. J Neuroinflammation 2020;17:25. [PMID: 31952509 DOI: 10.1186/s12974-020-1705-z] [Cited by in Crossref: 71] [Cited by in F6Publishing: 59] [Article Influence: 35.5] [Reference Citation Analysis]
40 Benakis C, Martin-Gallausiaux C, Trezzi JP, Melton P, Liesz A, Wilmes P. The microbiome-gut-brain axis in acute and chronic brain diseases. Curr Opin Neurobiol 2020;61:1-9. [PMID: 31812830 DOI: 10.1016/j.conb.2019.11.009] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 9.7] [Reference Citation Analysis]
41 Sankowski B, Księżarczyk K, Raćkowska E, Szlufik S, Koziorowski D, Giebułtowicz J. Higher cerebrospinal fluid to plasma ratio of p-cresol sulfate and indoxyl sulfate in patients with Parkinson's disease. Clin Chim Acta 2020;501:165-73. [PMID: 31726035 DOI: 10.1016/j.cca.2019.10.038] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
42 Reis J, Román GC, Giroud M, Palmer VS, Spencer PS. Medical management, prevention and mitigation of environmental risks factors in Neurology. Rev Neurol (Paris) 2019;175:698-704. [PMID: 31648732 DOI: 10.1016/j.neurol.2019.10.001] [Reference Citation Analysis]
43 Pu Y, Chang L, Qu Y, Wang S, Zhang K, Hashimoto K. Antibiotic-induced microbiome depletion protects against MPTP-induced dopaminergic neurotoxicity in the brain. Aging (Albany NY) 2019;11:6915-29. [PMID: 31479418 DOI: 10.18632/aging.102221] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]